1. Name and Address of Reporting Person
   
   JOHNSON & JOHNSON
   
   (Last)  (First)  (Middle)
   ONE JOHNSON & JOHNSON PLAZA
   
   (Street)
   NEW BRUNSWICK NJ 08933
   
   (City)  (State)  (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
   
   06/25/2020

3. Issuer Name and Ticker or Trading Symbol
   
   Fusion Pharmaceuticals Inc. [ FUSN ]

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
   
   Director  X  10% Owner
   Officer (give title below)
   Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)
   

6. Individual or Joint/Group Filing (Check Applicable Line)
   
   Form filed by One Reporting Person  X
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 4)</th>
<th>2. Amount of Securities Beneficially Owned (Instr. 4)</th>
<th>3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>4. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class A Preferred Shares</td>
<td>Common Shares 1,997,876</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
<tr>
<td>Class B Preferred Shares</td>
<td>Common Shares 947,640</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
<tr>
<td>Warrants to purchase Class B Preferred Shares</td>
<td>Common Shares 89,118</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
</tbody>
</table>

---

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 4)</th>
<th>2. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)</th>
<th>4. Conversion or Exercise Price of Derivative Security</th>
<th>5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)</th>
<th>6. Nature of Indirect Beneficial Ownership (Instr. 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class A Preferred Shares</td>
<td>(1)  (1)</td>
<td>Common Shares 1,997,876</td>
<td></td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
<tr>
<td>Class B Preferred Shares</td>
<td>(3)  (3)</td>
<td>Common Shares 947,640</td>
<td></td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
<tr>
<td>Warrants to purchase Class B Preferred Shares</td>
<td>01/10/2020(4)  01/10/2022(4)</td>
<td>Common Shares 89,118</td>
<td>8.1(4)</td>
<td>I</td>
<td>By Johnson &amp; Johnson Innovation - JJDC, Inc. (2)</td>
</tr>
</tbody>
</table>

---

1. Name and Address of Reporting Person

   JOHNSON & JOHNSON
   
   (Last)  (First)  (Middle)
   ONE JOHNSON & JOHNSON PLAZA
   
   (Street)
   NEW BRUNSWICK NJ 08933
   
   (City)  (State)  (Zip)

1. Name and Address of Reporting Person

   Johnson & Johnson Innovation - JJDC,
Explanation of Responses:
1. The Class A Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class A Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class A Preferred Shares have no expiration date.
2. The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.
3. The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class B Preferred Shares have no expiration date.
4. Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become Warrants to purchase Common Shares at an exercise price of $8.10 per share.

Remarks:

Johnson & Johnson By: /s/ Matthew Orlando, Secretary 06/25/2020
Johnson & Johnson Innovation - JJDC, Inc. By: /s/ Kevin Norman, Assistant Secretary 06/25/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.